WO2010019856A1 - Procédés et nécessaires de traitement des accidents vasculaires cérébraux et autres affections neurologiques - Google Patents

Procédés et nécessaires de traitement des accidents vasculaires cérébraux et autres affections neurologiques Download PDF

Info

Publication number
WO2010019856A1
WO2010019856A1 PCT/US2009/053839 US2009053839W WO2010019856A1 WO 2010019856 A1 WO2010019856 A1 WO 2010019856A1 US 2009053839 W US2009053839 W US 2009053839W WO 2010019856 A1 WO2010019856 A1 WO 2010019856A1
Authority
WO
WIPO (PCT)
Prior art keywords
propylnoraporphine
brain injury
compound
subject
pharmaceutically acceptable
Prior art date
Application number
PCT/US2009/053839
Other languages
English (en)
Inventor
Seth Finklestein
Marc Charette
John L. Neumeyer
Ross J. Baldessarini
Original Assignee
The Mclean Hospital Corporation
Neurocyte Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Mclean Hospital Corporation, Neurocyte Pharmaceuticals, Inc. filed Critical The Mclean Hospital Corporation
Publication of WO2010019856A1 publication Critical patent/WO2010019856A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom

Definitions

  • the invention relates to the treatment of stroke and other neurological conditions.
  • Stroke is the third leading cause of death and disability in the U.S., with an incidence of over 700,000 cases per year, and a prevalence of over 5 million.
  • the majority of strokes are ischemic, due to thromboembolic occlusion of a cerebral artery (85% of cases); the remainder are due to intracerebral hemorrhage (15% of cases).
  • Stroke generally causes focal damage to the brain, resulting in motor, sensory, cognitive, memory, visual, coordination, gait and other neurological deficits, depending on the size and location of focal brain injury. Although damaged brain regions do not regenerate after stroke, some degree of spontaneous neurological recovery can occur, due to structural and functional reorganization of remaining intact brain tissue.
  • Stroke generally presents as the abrupt onset of focal neurologic deficit.
  • the deficit may remain fixed, it may improve or progressively worsen, leading usually to irreversible neuronal damage at the core of the ischemic focus, whereas neuronal dysfunction in the penumbra may be treatable and or reversible.
  • Prolonged periods of ischemia result in tissue necrosis. Cerebral edema follows and progresses over the subsequent 2 to 5 days. If the region of the infarction is large, the edema may produce considerable mass effect with all of its attendant consequences.
  • ATTORNEY DOCKET NO. 04843/170WO2 vascular occlusion and its immediate consequences to the brain e.g., thrombolytics and neuroprotective treatments.
  • Stroke recovery-promoting treatments promote repair and reorganization of the damaged brain.
  • Traumatic brain injury is also one of the most serious reasons for hospital admission and disability in modem society. Clinical experience suggests that TBI may be classified into primary damage occurring immediately after injury, and secondary damage, which occurs during several days post injury. Current therapy of TBI is either surgical or else mainly symptomatic. Brain injury can also occur when the brain is globally deprived of oxygen. Anoxic-ischemic brain injuries occur when the brain receives little or no oxygen, such as with a cardiac arrest victim or a near-drowning victim.
  • Anoxic-ischemic brain injuries may result from airway obstruction, near- drowning, throat swelling, choking, strangulation, crush injuries to the chest, electrical shock, lightening strike, trauma to the head or neck, blood loss, shock, vascular disruption, heart attack, arteriovenous malformation, aneurysm, intracranial surgery, intracranial tumor, infectious disease, meningitis, metabolic disorders, hepatic encephalopathy, uremic encephalopathy, seizure disorders, lead poisoning, carbon monoxide poisoning, cardiac arrest, coronary artery bypass graft (CABG) surgery, and other conditions.
  • Other neurological conditions resulting in brain injury include
  • brain cells including neurons
  • Treatments that promote brain cell (neuronal) survival and neurological recovery are also likely to promote recovery in these other conditions as well.
  • Stroke and other types of brain injuries result in neurological abnormalities, including motor, sensory, cognitive, memory, visual, coordination, gait, and other deficits. Such deficits may result in significant PATENT
  • the invention features methods and kits for treating stroke and other neurological conditions in a subject by administering R(-)-l 1 -O-valeryl-N-H- propylnoraporphine or an analogue thereof.
  • the invention features a method of treating a subject suffering from stroke by administering to the subject an effective amount of a compound selected from i?(-)-l l-O-valeryl-N- «-propylnoraporphine and analogues thereof, or a pharmaceutically acceptable salt thereof.
  • the compound is administered in an amount effective to aid recovery of motor, sensory, cognitive, memory, visual, coordination, or gait deficits resulting from the stroke.
  • the compound is administered within six months, four months, three months, two months, one month, 14 days, 7 days, 3 days, 2 days, or one day following said stroke.
  • the compound is administered for a period of from 7 to 180 days, 1 to 180 days, 1 to 120 days, 1 to 90 days, 1 to 60 days, 1 to 30 days, 7 to 120 days, 7 to 90 days, 7 to 60 days, 7 to 30 days, 14 to 180 days, 14 to 120 days, 14 to 90 days, 14 to 60 days, 14 to 30 days, 21 to 180 days, 30 to 180 days, 60 to 180 days, or 90 to 180 days to aid recovery of motor, sensory, cognitive, memory, visual, coordination, or gait deficits resulting from the stroke.
  • the method includes ameliorating stroke, or the symptoms of stroke, in a subject displaying symptoms of stroke by administering the compound to the subject within 24 hours, 12 hours, 8 hours, 6 hours, 5 hours, 4 hours, 90 minutes, 1 hour, 45 minutes, 30 minutes, or 15 minutes of said stroke.
  • the invention further features a method of treating a subject suffering from a traumatic brain injury by administering to the subject an effective amount of a compound selected from R(-)-l 1-O-valeryl-N-H- propylnoraporphine and analogues thereof, or a pharmaceutically acceptable salt thereof.
  • the invention also features a method of treating a subject suffering from an anoxic-ischemic brain injury by administering to the subject an effective amount of a compound selected from R(-)-l l-O-valeryl-N- «- propylnoraporphine and analogues thereof, or a pharmaceutically acceptable salt thereof.
  • the invention features a method of treating a subject suffering from a non-traumatic brain injury selected from Alzheimer's disease, Huntington's disease, multiple sclerosis, amyotrophic lateral sclerosis, brain hemorrhage, brain infections, and brain tumor by administering to the subject an effective amount of a compound selected from R(-)- 11 -O-valeryl-N-r ⁇ - propylnoraporphine and analogues thereof, or a pharmaceutically acceptable salt thereof.
  • the non-traumatic brain injury is Alzheimer's disease and the compound is administered chronically throughout the life of the subject.
  • the compound is administered in an amount effective to aid neurological recovery.
  • the invention further features a method of aiding recovery of cognitive function following brain injury in a subject by administering to the subject an effective amount of a compound selected from R(-)-l l-O-valeryl-N- «- propylnoraporphine and analogues thereof, or a pharmaceutically acceptable salt thereof.
  • the brain injury is a consequence of a stroke, traumatic brain injury, non-traumatic brain injury, or anoxic-ischemic brain injury.
  • the invention features a method of aiding neurological recovery following brain injury in a subject by administering to the subject an effective amount of a compound selected from R(-)-l 1-O-valeryl-N-w- propylnoraporphine and analogues thereof, or a pharmaceutically acceptable salt thereof.
  • the brain injury is a consequence of a stroke, traumatic brain injury, non-traumatic brain injury, anoxic-ischemic brain injury, or other neurological conditions.
  • the compound is administered in an amount effective to aid recovery of motor, sensory, cognitive, memory, visual, coordination, or gait deficits resulting from brain injury.
  • the compound is administered to the subject in an average daily dose of between 0.25 and 25 mg/kg/day, 0.75 and 20 mg/kg/day, 0.75 and 5 mg/kg/day, 1.5 and 25 mg/kg/day, 1.5 and 5 mg/kg/day, 2.5 and 20 mg/kg/day, 2.5 and 5 mg/kg/day, 3 and 20 mg/kg/day, or 3 and 10 mg/kg/day.
  • the compound is administered daily for a period of 1 to 180 days, 1 to 120 days, 1 to 90 days, 1 to 60 days, 1 to 30 days, 1 to 15 days, 1 to 7 days, or 1 to 5 days.
  • the compound is administered orally, intravenously, or subcutaneously.
  • the methods further includes the administration of an effective amount of an anti-emetic agent (e.g., nicotine, lobclinc sulfate, pipamazine, oxypendyl hydrochloride, ondansetron, buclizine hydrochloride, cyclizine hydrochloride, dimcnhydrinate, scopolamine, metopimazine, benzauinamine hydrochloride or diphenidol hydrochloride).
  • an anti-emetic agent e.g., nicotine, lobclinc sulfate, pipamazine, oxypendyl hydrochloride, ondansetron, buclizine hydrochloride, cyclizine hydrochloride, dimcnhydrinate, scopolamine, metopimazine, benzauinamine hydrochloride or diphenidol hydrochloride.
  • kits including: (i) a pharmaceutical composition including a pharmaceutically acceptable excipient and a compound selected from R(-)-l l-O-valeryl-N-rc-propylnoraporphine and PATENT
  • the kit further includes instructions for administering the compound to a subject to aid recovery of motor, sensory, cognitive, memory, visual, coordination, or gait deficits resulting from the stroke.
  • the kit includes instructions for administering said compound to the subject within six months, four months, three months, two months, one month, two weeks, one week, 5 days, 3 days, 2 days, or 1 day after the stroke.
  • the invention further features a kit including: (i) a pharmaceutical composition including a pharmaceutically acceptable excipient and a compound selected from i?(-)-l 1-O-valeryl-N-rc-propylnoraporphine and analogues thereof, or a pharmaceutically acceptable salt thereof; and (ii) instructions for administering the compound to a subject for the treatment of a traumatic brain injury.
  • the invention also features a kit including: (i) a pharmaceutical composition including a pharmaceutically acceptable excipient and a compound selected from R(-)-l l-O-valeryl-N- «-propylnoraporphine and analogues thereof, or a pharmaceutically acceptable salt thereof; and (ii) instructions for administering the compound to a subject for the treatment of an anoxic- ischemic brain injury.
  • the invention features a kit including: (i) a pharmaceutical composition including a pharmaceutically acceptable excipient and a compound selected from R(-)- 11 -O-valeryl-N- ⁇ -propylnoraporphine and analogues thereof, or a pharmaceutically acceptable salt thereof; and (ii) instructions for administering the compound to a subject for the treatment of a non-traumatic brain injury selected from Alzheimer's disease, Huntington's disease, multiple sclerosis, PATENT
  • the non-traumatic brain injury is Alzheimer's disease.
  • the invention further features a kit including: (i) a pharmaceutical composition including a pharmaceutically acceptable excipient and a compound selected from /?(-)- 1 l-O-valeryl-N- «-propylnoraporphine and analogues thereof, or a pharmaceutically acceptable salt thereof; and (ii) instructions for administering the compound for aiding recovery of cognitive function following brain injury in a subject.
  • the brain injury is a consequence of a stroke, traumatic brain injury, non-traumatic brain injury, or anoxic-ischemic brain injury.
  • the invention features a kit including: (i) a pharmaceutical composition including a pharmaceutically acceptable excipient and a compound selected from i?(-)-l 1-O-valeryl-N-r ⁇ -propylnoraporphine and analogues thereof, or a pharmaceutically acceptable salt thereof; and (ii) instructions for administering the compound to aid neurological recovery following brain injury in a subject.
  • the brain injury is a consequence of a stroke, traumatic brain injury, non-traumatic brain injury, or anoxic-ischemic brain injury.
  • the kit includes instructions for administering the compound to a subject to aid recovery of motor, sensory, cognitive, memory, visual, coordination, or gait deficits resulting from brain injury.
  • the kit includes instructions for administering daily from 2.5 to 1,200 mg, 2.5 to 1,000 mg, 5 to 1,000 mg, 10 to 1,000 mg, 25 to 1,000 mg, 50 to 1,000 mg, 50 to 800 mg, 100 to 1,000 mg, 100 to 700 mg, 200 to 1 ,000 mg, 200 to 800 mg, 200 to 700 mg, 200 to 500 mg, 300 to 1,000 mg, 300 to 800 mg, 300 to 600 mg, 400 to 1,000 mg, 400 to 800 mg, or 400 to 600 mg of the compound to the subject.
  • the pharmaceutical composition is formulated for oral administration, intravenous administration, or subcutaneous administration.
  • the compound is R(-)- 1 1 -O-valcryl-N-n-propylnorapo ⁇ hine or a pharmaceutically acceptable salt thereof.
  • the compound is an analogue of the formula:
  • Y 1 is C(O)-R 3 or fatty acid acyl
  • X 1 is H, F, OH, or OCH 3
  • R 2 is H, CH 3 , or OCH 3
  • R 3 is ethyl, ⁇ -propyl, isopropyl, cyclopropyl, cyclopropylmethyl, cyclopropylethyl, w-butyl, /s ⁇ -butyl, sec-butyl, tert-butyl, vinyl, allyl, 2- cyclopropyl- 1 -ethenyl, 1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methyl-l- propenyl, 2-methyl-2-propenyl, ethynyl, 1-propynyl, 2-propyn
  • the compound has the above formula wherein Y 1 is fatty acid acyl; Xj is H; R 1 is CH 2 CH 2 CH 3 ; and R 2 is H.
  • the compound is an analogue selected from R(-)-l l-O- isobutyryl-N-r ⁇ -propylnoraporphine, R(-)- 11 -O-butyryl-N-r ⁇ - propylnoraporphine, R(-)- ⁇ l-O-isovaleryl-N- «-propylnoraporphine, R( -)-10- methyl-1 1-O-butyryl-N-ft-propylnoraporphine, /?(-)- 10-methyl- 1 l-O- isovaleryl-N-rz-propylnoraporphine, R(-)- 10-methyl- 11 -O-valeryl-N-r ⁇ - propylnoraporphine, /
  • ATTORNEY DOCKET NO. 04843/170WO2 propylnoraporphine R(-)- 10-methoxy- 11 -O-butyryl-N-r ⁇ -propylnoraporphine, /?(-)- 10-methoxy- 11 -O-isovaleryl-N-rc-propylnoraporphine, /?(-)- 10-methoxy- 11-O-valeryl-N-w-propylnoraporphine, i?(-)-2-fluoro-l l-O-isobutyryl-N-77- propylnoraporphine, i?(-)-2-fluoro- 1 l-O-butyryl-N- «-propylnoraporphine, R(- )-2-fluoro-l 1-O-isovaleryl-N-w-propylnoraporphine, and R(-)-2-fluoro- 1 l-O
  • the invention features a pharmaceutical composition formulated for oral administration in unit dosage form (e.g., a tablet, capsule, caplet, lozenge, etc.), the unit dosage form including a pharmaceutically acceptable excipient and from 50 mg to 900 mg, 50 mg to 750 mg, 100 mg to 900 mg, 100 mg to 750 mg, 100 mg to 500 mg, 200 mg to 900 mg, 200 mg to 750 mg, 200 mg to 500 mg, 300 mg to 900 mg, 300 mg to 750 mg, 400 mg to 900 mg, or 400 mg to 600 mg of R( -)-l 1-O-valeryl-N-r ⁇ -propylnoraporphine or a pharmaceutically acceptable salt thereof.
  • unit dosage form e.g., a tablet, capsule, caplet, lozenge, etc.
  • the unit dosage form including a pharmaceutically acceptable excipient and from 50 mg to 900 mg, 50 mg to 750 mg, 100 mg to 900 mg, 100 mg to 750 mg, 100 mg to 500 mg, 200 mg to 900
  • stroke refers to a clinical event involving thrombotic or embolic occlusion of a blood vessel supplying the brain, or a brain hemorrhage. Occlusion or hemorrhage can involve brain arteries or veins. Typically, stroke is manifest by the abrupt onset of a focal neurologic deficit.
  • ischemic stroke refers to stroke characterized by localized tissue anemia due to obstruction of the inflow of arterial blood. Ischemic stroke is usually caused by atherothrombosis or embolism of a major cerebral artery, but may also be caused by coagulation disorders or nonatheromatous vascular disease.
  • treating stroke includes administration of a compound of the present invention, or a pharmaceutically acceptable salt thereof, for the purpose of (1) preventing stroke, (2) inhibiting stroke or the symptoms of stroke in a subject that is experiencing or displaying the pathology or symptomatology of stroke (i.e., arresting further development of the pathology and/or symptomatology), (3) ameliorating stroke or the symptoms of stroke in a subject that is experiencing or displaying the pathology or PATENT
  • ATTORNEY DOCKET NO. 04843/170WO2 symptomatology of stroke i.e., reversing the pathology and/or symptomatology
  • (4) enhancing functional recovery following stroke or reducing hospitalization following stroke i.e., reversing the pathology and/or symptomatology
  • the methods and kits of the invention can be used for preventing, treating, eradicating, ameliorating or otherwise reducing the severity of stroke.
  • the methods and kits can be used to treat acute stroke (e.g., therapy beginning within 3 hours of a stroke event), as well as for stroke recovery (e.g., therapy beginning at least 8 hours following a stroke event).
  • brain injury is a general term used to refer to a condition that results in central nervous system damage, irrespective of its pathophysiological basis.
  • a "brain injury” Among the most frequent origins of a "brain injury” are stroke and traumatic brain injury (TBI).
  • traumatic brain injury and "TBl” refer to traumatic injuries to the brain which occur when physical trauma causes brain damage.
  • TBI can result from a closed head injury or a penetrating head injury.
  • non-traumatic brain injury refers to brain injuries that do not involve ischemia or external mechanical force (e.g. stroke, Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, amyotrophic lateral sclerosis, brain hemorrhage, brain infections, brain tumor, among others).
  • ischemia e.g. stroke, Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, amyotrophic lateral sclerosis, brain hemorrhage, brain infections, brain tumor, among others.
  • anoxic-ischemic brain injury refers to deprivation of oxygen supply to brain tissue resulting in compromised brain function and includes cerebral hypoxia.
  • anoxic-ischemic brain injury includes focal cerebral ischemia, global cerebral ischemia, hypoxic hypoxia (i.e., limited oxygen in the environment causes reduced brain function, such as with divers, aviators, mountain climbers, and fire fighters, all of whom are at risk for this kind of cerebral hypoxia), obstructions in the lungs (e.g., hypoxia resulting from choking, strangulation, the crushing of the windpipe, PATENT
  • ATTORNEY DOCKET NO. 04843/170WO2 and severe asthma hypemic hypoxia (i.e., reduced brain function is caused by inadequate oxygen in the blood despite adequate environmental oxygen, as with anemia and carbon monoxide poisoning), and ischemic hypoxia (e.g., hypoxia is caused by inadequate blood flow to the brain, such as with stroke, shock, heart attacks, and by conditions exerting pressure on the brain an impede absorption of oxygen, such as cerebral edema, brain hemorrhages, and hydrocephalus).
  • hypemic hypoxia i.e., reduced brain function is caused by inadequate oxygen in the blood despite adequate environmental oxygen, as with anemia and carbon monoxide poisoning
  • ischemic hypoxia e.g., hypoxia is caused by inadequate blood flow to the brain, such as with stroke, shock, heart attacks, and by conditions exerting pressure on the brain an impede absorption of oxygen, such as cerebral edema, brain hemorrhages, and hydrocephalus).
  • administration refers to a method of giving a dosage of a pharmaceutical composition to a patient, where the method is, e.g., oral, topical, transdermal, by inhalation, intravenous, intraperitoneal, intracerebroventricular, intrathecal, or intramuscular.
  • the preferred method of administration can vary depending on various factors, e.g., the components of the pharmaceutical composition, site of administration, and severity of the symptoms being treated.
  • an amount effective and “effective amount” refer to the amount ofR(-)-l l-O-valeryl-N-w-propylnoraporphine, analogue thereof, or pharmaceutically acceptable salt thereof, required to treat a condition associated with brain injury.
  • the effective amount used to practice the invention for therapeutic treatment of conditions caused by, or contributed to by, brain injury can vary depending upon the manner of administration, the age, body weight, and general health of the subject. Ultimately, the attending physician will decide the appropriate amount and dosage regimen. Such amount is referred to as an "effective" amount.
  • shocking cognitive function is meant using the methods of the invention to improve memory, communication, attention, perception, recognition, planning, or related skills in a subject having impaired cognitive function as a result of a brain injury in comparison to a subject suffering a brain injury of the same severity and type but left untreated.
  • aiding neurological recovery is meant using the methods of the invention to ameliorate neurological abnormalities, such as motor, sensory, cognitive, memory, visual, coordination, and gait deficits in a subject having such neurological deficits as a result of a brain injury in comparison to a subject suffering a brain injury of the same severity and type but left untreated.
  • neurological abnormalities such as motor, sensory, cognitive, memory, visual, coordination, and gait deficits
  • average daily dose is meant the administered dose of R(-)-l 1-0- valeryl-N-/2-propylnorapo ⁇ hine, or an analogue thereof, per unit time.
  • the average daily dose is calculated from the instructed regimen. For example, oral dosing of 10 mg twice weekly is an average daily dose of 2.87 mg/day (i.e., 20 mg/7 days).
  • the average daily dose is calculated from the average of the high and low values. For example, a regimen that calls for 150 mg over seven to ten days has an average daily dose of 18.2 mg/day ((150 mg/7 days + 150 mg/10 days)/2).
  • subject any mammal (e.g., a human).
  • Other animals that can be treated using the methods and kits of the invention include horses, dogs, cats, pigs, goats, rabbits, hamsters, and monkeys.
  • treating refers to administering a pharmaceutical composition for prophylactic and/or therapeutic purposes.
  • To “prevent disease” refers to prophylactic treatment of a patient who is not yet ill, but who is susceptible to, or otherwise at risk of, a particular disease.
  • To “treat disease” or use for “therapeutic treatment” refers to administering treatment to a patient already suffering from a disease to ameliorate the disease and improve the patient's condition.
  • treating is the administration to a mammal either for therapeutic or prophylactic purposes.
  • compositions of the invention include /?(-)- 11 -O- valeryl-N-r ⁇ -propylnoraporphine, or an analogue thereof, having a substantially R(-) enantiomeric configuration.
  • This configuration refers to the stereochemical orientation of the fused ring system (i.e., the only stereocenter in R(-)- ⁇ 1-O-valeryl-N-r ⁇ -propylnoraporphine).
  • ATTORNEY DOCKET NO. 04843/170WO2 substantially R(-) enantiomeric configuration is one having an enantiomeric excess in the R(-) configuration of at least 70%, 80%, 90%, 95%, 97%, 98%, 99%, or 99.5%.
  • analogue or “analogues” refers to compounds of any of formulas I-I V, or a pharmaceutically acceptable salt or solvate thereof.
  • Y 1 is C(O)-R 3 , C(O)-O-R 3 , C(O)-NR 3 R 4 , P(O)(OH)-O-R 3 , C(S)- R 3 , C(S)-O-R 3 , C(S)-NR 3 R 4 , or fatty acid acyl;
  • X 1 is H, F, Cl, Br, I, OH, OCH 3 , or OC(O)-R 5 ;
  • R 1 is H, C 1 ⁇ alkyl, C 2 ⁇ 1 alkenyl, or C 2 ⁇ alkynyl;
  • R 2 is H, CH 3 , or OCH 3 ; each of R 3 and R 4 is, independently, selected from II, C 1 _ 12 alkyl, C 2 - I2 alkenyl, C 2 _ 12 alkynyl, C 2 - 6 heterocyclyl, C 6 ⁇ 2 aryl, C 7 _ 14 alkaryl, C 3 _ 10
  • Compounds of formula I include those described by formulas II or a pharmaceutically acceptable salt or solvate thereof.
  • X 1 is H, F, Cl, Br ; I, OH, or OCH 3 ;
  • R 2 is H, CH 3 , or OCH 3 ;
  • R 3 is methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclopropylmethyl, cyclopropylethyl, r ⁇ -butyl, w ⁇ -butyl, sec-butyl, tert-butyl, vinyl, allyl, 2- cyclopropyl-1-ethenyl, 1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methyl-l- propenyl, 2-methyl-2-propenyl, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2- butynyl, or 3-butynyl.
  • Compounds of formula II include R(-)- 11 -O-acetyl-N-r ⁇ - propylnoraporphine, /?(-)- 1 l-O-propionyl-N- «-propylnorap ⁇ hine, R(-)-l 1-0- isobutyryl-N-r ⁇ -propylnorapo ⁇ hine, i?(-)-l 1-O-butyryl-N-n- propylnoraporphine, /?(-)- 1 l-O-isovaleryl-N-w-propylnoraporphine, R(-)-lO- methyl-1 l-O-acetyl-N-r ⁇ -propylnoraporphine, /?(-)-!
  • X 1 is H, F, Cl, Br, I, OH, or OCH 3 ;
  • R 2 is H, CH 3 , or OCH 3 ;
  • R 3 is H, methyl, ethyl, ⁇ -propyl, isopropyl, cyclopropyl, cyclopropylmethyl, cyclopropylethyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, vinyl, allyl, 2- cyclopropyl-1-ethenyl, 1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methyl-l- propenyl, 2-methyl-2-propenyl, ethynyl, 1-propynyl, 2-propynyl, 1-butyny
  • Compounds of formula III include R(-)-l l-O- methylcarbamoyl-N-r ⁇ -propylnorapo ⁇ hine, R(-)- 11 -O-ethylcarbamoyl-N-fl- propylnoraporphine, /?(-)- 1 1 -O-isopropylcarbamoyl-N-tt-propylnoraporphine, R(-)-l 1-O-r ⁇ -propylcarbamoyl-N-n-propylnorapo ⁇ hine, /?(-)- 1 l-O- isobutylcarbamoyl-N- ⁇ -propylnoraporphine, R(-)- 11 -O-n-butylcarbamoyl-N-rc- propylnoraporphine, i?(-)-l 0-methyl- 11-O-methylcarbamoyl-
  • ATTORNEY DOCKET NO. 04843/170WO2 propylnoraporphine i?(-)-2-fluoro-l 1 -O-methylcarbamoyl-N-w- propylnoraporphine, /?(-)-2-fluoro-l 1-O-ethylcarbamoyl-N-r ⁇ - propylnoraporphine, R(-)-2-fluoro- 1 l-O-isopropylcarbamoyl-N-r ⁇ - propylnoraporphine, i?(-)-2-fluoro-l 1 -O-r ⁇ -propylcarbamoyl-N-rc- propylnoraporphine, R(-)-2-fluoro- 11 -O-isobutylcarbamoyl-N-r ⁇ - propylnoraporphine, and R(-)-2-fluoro- 1 l-O
  • X 2 is F, Cl, Br, I, OH, OCH 3 , or OC(O)-R 13 ;
  • R 11 is H, C 1 ⁇ alkyl, C 2 _ 4 alkenyl, or C 2 _ 4 alkynyl;
  • R 12 is H, CH 3 , or OCH 3 ; and
  • R 13 is C 1-4 alkyl, C 2 ⁇ alkenyl, or C 2 ⁇ alkynyl.
  • Analogues of /?(-)- 11-O-valeryl-N-r ⁇ -propylnoraporphine can be prepared as described in PCT Publication No. WO/2005/099702, published October 27, 2005.
  • the number of atoms of a particular type in a substituent group is generally given as a range, e.g., an alkyl group containing from 1 to 4 carbon atoms or C 1-4 alkyl. Reference to such a range is intended to include specific references to groups having each of the integer number of atoms within the specified range.
  • an alkyl group from 1 to 4 carbon atoms includes each of C 1 , C 2 , C 3 , and C 4 .
  • a Ci_ )2 heteroalkyl for example, includes from 1 to 12 carbon atoms in addition to one or more heteroatoms. Other numbers of atoms and other types of atoms may be indicated in a similar manner.
  • alkyl and the prefix “alk-” are inclusive of both straight- chain and branched- chain groups and of cyclic groups, i.e., cycloalkyl.
  • Cyclic groups can be monocyclic or polycyclic and preferably have from 3 to 6 ring carbon atoms, inclusive.
  • Exemplary cyclic groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl groups.
  • C 1 ⁇ alkyl is meant a branched or unbranched hydrocarbon group having from 1 to 4 carbon atoms.
  • a C 1 ⁇ alkyl group may be substituted or unsubstituted.
  • substituents include alkoxy, aryloxy, sulfhydryl, alkylthio, arylthio, halide, hydroxyl, fluoroalkyl, perfluoralkyl, amino, aminoalkyl, disubstituted amino, quaternary amino, hydroxyalkyl, carboxyalkyl, and carboxyl groups.
  • C 1 ⁇ alkyls include, without limitation, methyl, ethyl, n- propyl, isopropyl, cyclopropyl, cyclopropylmethyl, rc-butyl, /so-butyl, sec-butyl, tert-butyl, and cyclobutyl.
  • C 1 ⁇ 12 alkyl is meant a branched or unbranched hydrocarbon group having from 1 to 12 carbon atoms.
  • a C ⁇ n alkyl may be substituted or unsubstituted, may optionally include monocyclic or polycyclic rings, and includes the C 1 ⁇ alkyls above.
  • C 2 - 4 alkenyl is meant a branched or unbranched hydrocarbon group containing one or more double bonds and having from 2 to 4 carbon atoms.
  • a C 2 ⁇ alkenyl may optionally include monocyclic or polycyclic rings, in which each ring desirably has from three to six members.
  • the C 2 ⁇ alkenyl group may be substituted or unsubstituted.
  • substituents include alkoxy, aryloxy, sulfhydryl, alkylthio, arylthio, halide, hydroxyl, fluoroalkyl, perfluoralkyl, amino, aminoalkyl, disubstituted amino, quaternary amino, hydroxyalkyl, carboxyalkyl, and carboxyl groups.
  • C 2 ⁇ alkenyls include, without limitation, vinyl, allyl, 2-cyclopropyl-l-ethenyl, 1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methyl- 1-propenyl, and 2-methyl-2-propenyl.
  • C 2 - 12 alkenyl is meant a branched or unbranched hydrocarbon group containing one or more double bonds and having from 2 to 12 carbon PATENT
  • a C 2 _ 12 alkenyl may be substituted or unsubstituted, may optionally include monocyclic or polycyclic rings, and includes the C 2 ⁇ alkenyls above.
  • C 2 ⁇ alkynyl is meant a branched or unbranched hydrocarbon group containing one or more triple bonds and having from 2 to 4 carbon atoms.
  • a C 2 ⁇ alkynyl may optionally include monocyclic, bicyclic, or tricyclic rings, in which each ring desirably has five or six members.
  • the C 2 _ 4 alkynyl group may be substituted or unsubstituted.
  • substituents include alkoxy, aryloxy, sulfhydryl, alkylthio, arylthio, halide, hydroxy, fluoroalkyl, perfluoralkyl, amino, aminoalkyl, disubstituted amino, quaternary amino, hydroxyalkyl, carboxyalkyl, and carboxyl groups.
  • C 2 ⁇ t alkynyls include, without limitation, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, and 3-butynyl.
  • C 2 _i 2 alkynyl is meant a branched or unbranched hydrocarbon group containing one or more triple bonds and having from 2 to 12 carbon atoms.
  • a C 2 _i 2 alkynyl may be substituted or unsubstituted, may optionally include monocyclic or polycyclic rings, and includes C 2 ⁇ alkynyls above.
  • C 2 _ 6 heterocyclyl is meant a stable 5- to 7-membcrcd monocyclic or 7- to 14-membered bicyclic heterocyclic ring which is saturated partially unsaturated or unsaturated (aromatic), and which consists of 2 to 6 carbon atoms and 1 , 2, 3 or 4 heteroatoms independently selected from N, O, and S, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring.
  • the heterocyclyl group may be substituted or unsubstituted.
  • substituents include alkoxy, aryloxy, sulfhydryl, alkylthio, arylthio, halide, hydroxy, fluoroalkyl, perfluoralkyl, amino, aminoalkyl, disubstituted amino, quaternary amino, hydroxyalkyl, carboxyalkyl, and carboxyl groups.
  • the nitrogen and sulfur heteroatoms may optionally be oxidized.
  • the heterocyclic ring may be covalently attached via any heteroatom or carbon atom which results in a stable structure, e.g., an imidazolinyl ring may be linked at either of the ring-carbon atom positions or at PATENT
  • a nitrogen atom in the heterocycle may optionally be quaternized.
  • Heterocycles include, without limitation, lH-indazole, 2-pyrrolidonyl, 2H,6H- 1,5,2-dithiazinyl, 2H-pyrrolyl, 3H-indolyl, 4-piperidonyl, 4aH-carbazole, 4H- quinolizinyl, 6H-l,2,5-thiadiazinyl, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl, carbazolyl, 4aH-carbazolyl, b-carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinoliny
  • Preferred 5 to 6 membered heterocycles include, without limitation, pyridinyl, pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl, piperazinyl, piperidinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, and tetrazolyl.
  • C ⁇ 5 _i 2 aryl is meant an aromatic group having a ring system comprised of carbon atoms with conjugated ⁇ electrons (e.g., phenyl).
  • the aryl group has from 6 to 12 carbon atoms.
  • Aryl groups may optionally include monocyclic, bicyclic, or tricyclic rings, in which each ring desirably has five or six members.
  • the aryl group may be substituted or unsubstituted.
  • substituents include alkyl, hydroxy, alkoxy, aryloxy, sulfhydryl, alkylthio, arylthio, halide, fluoroalkyl, carboxyl, hydroxyalkyl, carboxyalkyl, amino, aminoalkyl, monosubstituted amino, disubstituted amino, and quaternary amino groups.
  • C 7 _ 14 alkaryl is meant an alkyl substituted by an aryl group (e.g., benzyl, phenethyl, or 3,4-dichlorophenethyl) having from 7 to 14 carbon atoms.
  • aryl group e.g., benzyl, phenethyl, or 3,4-dichlorophenethyl
  • C 3 _ 10 alkheterocyclyl is meant an alkyl substituted heterocyclic group having from 3 to 10 carbon atoms in addition to one or more heteroatoms (e.g., 3-furanylmethyl, 2-furanylmethyl, 3-tetrahydrofuranylmethyl, or 2- tetrahydrofuranylmethyl).
  • C]_ 7 heteroalkyl is meant a branched or unbranched alkyl, alkenyl, or alkynyl group having from 1 to 7 carbon atoms in addition to 1, 2, 3 or 4 heteroatoms independently selected from the group consisting of N, O, S, and P.
  • Heteroalkyls include, without limitation, tertiary amines, secondary amines, ethers, thioethers, amides, thioamides, carbamates, thiocarbamates, hydrazones, imines, phosphodiesters, phosphoramidates, sulfonamides, and disulfides.
  • a heteroalkyl may optionally include monocyclic, bicyclic, or tricyclic rings, in PATENT
  • ATTORNEY DOCKET NO. 04843/170WO2 which each ring desirably has three to six members.
  • the heteroalkyl group may be substituted or unsubstituted.
  • substituents include alkoxy, aryloxy, sulfhydryl, alkylthio, arylthio, halide, hydroxyl, fluoroalkyl, perfluoralkyl, amino, aminoalkyl, disubstituted amino, quaternary amino, hydroxyalkyl, hydroxyalkyl, carboxyalkyl, and carboxyl groups.
  • Examples of C]_ 7 heteroalkyls include, without limitation, methoxymethyl and ethoxyethyl.
  • halide is meant bromine, chlorine, iodine, or fluorine.
  • fluoroalkyl is meant an alkyl group that is substituted with a fluorine atom.
  • perfluoroalkyl is meant an alkyl group consisting of only carbon and fluorine atoms.
  • Carboxyalkyl is meant a chemical moiety with the formula -(R)-COOH, wherein R is selected from C 1- . ? alkyl, C 2 _ 7 alkenyl, C 2 _ 7 alkynyl, C 2 _ 6 heterocyclyl, C ⁇ 12 aryl, C 7 _ 14 alkaryl, C 3 _ 10 alkheterocyclyl, or Cj_ 7 heteroalkyl.
  • hydroxyalkyl is meant a chemical moiety with the formula -(R)- OH, wherein R is selected from C ⁇ 7 alkyl, C 2 _ 7 alkenyl, C 2 _ 7 alkynyl, C 2 ⁇ heterocyclyl,
  • alkoxy is meant a chemical substituent of the formula -OR, wherein R is selected from C]_ 7 alkyl, C 2 ⁇ 7 alkenyl, C 2 ⁇ 7 alkynyl, C 2 _ 6 heterocyclyl, C 6 ⁇ 2 aryl, C 7 _ H alkaryl, C 3 _ 10 alkheterocyclyl, or C]_ 7 heteroalkyl.
  • aryloxy is meant a chemical substituent of the formula -OR, wherein R is a C 6 ⁇ 2 aryl group.
  • alkylthio is meant a chemical substituent of the formula -SR, wherein R is selected from C 1 . ? alkyl, C 2 _ 7 alkenyl, C 2 _ 7 alkynyl, C 2 _ 6 heterocyclyl, C 6 - J 2 aryl, C 7 _ H alkaryl, C 3 _i 0 alkheterocyclyl, or C]_ 7 heteroalkyl.
  • arylthio is meant a chemical substituent of the formula -SR, wherein R is a C 6 ⁇ 2 aryl group.
  • quaternary amino is meant a chemical substituent of the formula -(R)-N(R')(R")(R'") + , wherein R, R', R", and R'" are each independently an alkyl, alkenyl, alkynyl, or aryl group.
  • R may be an alkyl group linking the quaternary amino nitrogen atom, as a substituent, to another moiety.
  • the nitrogen atom, N is covalently attached to four carbon atoms of alkyl and/or aryl groups, resulting in a positive charge at the nitrogen atom.
  • fatty acid acyl is meant a chemical moiety with the formula R- C(O)-, wherein R is a partially-saturated straight- chain or branched hydrocarbon group having between 12 and 26 carbon atoms.
  • Fatty acid acyls are derived from fatty acids including, without limitation, those occurring naturally in the brain.
  • fatty acids having 16 carbon atoms and 0, 1 or 2 double bonds (C 16:0; C 16:1 and C 16:2), those with 18 carbon atoms and 1, 2 or 3 double bonds (C18:l ; C18:2; and C18:3), those with 20 carbon atoms and 1, 2 or 4 double bonds (C20:l; C20:2; and C20:4) and those with 22 carbon atoms and 4, 5 or 6 double bonds (C22:4; C22:5 and C22:6).
  • the fatty acids can be substituted or unsubstituted.
  • Exemplary substituents include hydroxyl, halide, methyl, ethyl, propyl, isopropyl, butyl, and pentyl groups.
  • the fatty acid acyl is 4, 7, 10, 13, 16, 19 docosahexanoyl.
  • the invention features derivatives of /?(-)- 1 1 -hydroxy aporphines and their use for the treatment of stroke and other neurological conditions.
  • the compounds can exhibit enhanced bioavailability and extended in vivo half lives in comparison to /?(-)-apomorphine ("apomorphine").
  • apomorphine /?(-)-apomorphine
  • the compounds of the invention can be administered in a more convenient and less invasive manner than currently used for apomorphine therapy.
  • Figure 1 is a chart depicting the study design (e.g., handling, surgery, injections and sacrifice timetable) of R(-)-l 1-O-valeryl-N-w- propylnoraporphine in a rat stroke recovery model. Further details are provided in Example 1.
  • Figure 3 is a graph depicting the results of a hindlimb placing test in undosed rats and rats dosed with R(—)-l 1-O-valeryl-N-rc-propylnoraporphine twice daily (BID) at 0.625mg/kg, 1.250 mg/kg, and 2.500 mg/kg (total daily dosing - 1.250, 2.500, or 5.000 mg/kg of body- weight, respectively) for a period of 7 days following stroke. (* /K0.05; ** /K ⁇ .01, *** /? ⁇ 0.001). These observations indicate a dose-dependent increase in favorable functional improvements compared with an inactive placebo-treatment condition.
  • BID R(-)- ⁇ l-O-valeryl-N-r ⁇ -propylnoraporphine twice daily
  • the invention features methods and kits for treating stroke and related conditions in a subject by administering R(-)- 11 -O-valeryl-N-n- propylnoraporphine or an analogue thereof.
  • Neurological Conditions Representative examples of conditions treatable using compounds of the present invention are as listed hereinabove, and include, but are not limited to, stroke, traumatic brain injury, anoxic-ischemic brain injury, or other conditions of non- traumatic brain injury, including Alzheimer's disease, Huntington's Disease, amyotrophic lateral sclerosis, multiple sclerosis, and brain infections and tumors. These conditions have in common loss of brain cells (esp. neurons), resulting in neurological dysfunction. All of these conditions can improve or recover to some degree, following treatment using the methods of the invention. Without being bound by any theory, it appears that following brain injury the compounds in the methods of the invention stimulate recovery pathways through activation of brain dopamine receptors.
  • R(-)- 1 1 -0-valeryl-N-n-propylnoraporphine, and analogues thereof can be administered following a stroke, or brain injury due to other neurological conditions, to reduce the loss of brain function and/or restore some lost brain function. Accordingly, the motor, sensory, cognitive, memory, visual, coordination or other neurological deficits of a subject having one of the above conditions and undergoing the therapy of the invention are improved in comparison to a subject suffering a condition of the same severity and type but left untreated.
  • Formulations of R(-)-l l-O-valeryl-N-n-propylnoraporphine, and analogues thereof may be in the form of liquid solutions or suspensions; for oral administration, formulations may be in the form of tablets or capsules; and for intranasal formulations, in the form of powders, nasal drops, or aerosols. Methods well known in the art for making formulations are found, for example, in "Remington: The Science and Practice of Pharmacy” (20th ed., editors: A.R. Gennaro AR., 2000, Philidelphia: Lippincott- Williams & Wilkins).
  • Formulations for parenteral administration may, for example, contain excipients, sterile water, or saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated napthalenes.
  • Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the compounds.
  • Nanoparticulate formulations e.g., biodegradable nanoparticles, solid lipid nanoparticles, liposomes
  • parenteral delivery systems include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes.
  • Formulations for inhalation may contain excipients, for example, lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycolate and deoxycholate, or may be oily solutions for administration in the form of nasal drops, or as a gel.
  • concentration of the compound in the formulation will vary depending upon a number of factors, including the dosage of the drug to be administered, and the route of administration.
  • the compound may be optionally administered as a pharmaceutically acceptable salt, such as a non-toxic acid addition salts or metal complexes that are commonly used in the pharmaceutical industry. Examples of acid addition salts include organic acids such as acetic, lactic, pamoic, maleic, citric, malic, ascorbic, succinic, benzoic, palmitic, suberic, salicylic, tartaric, P
  • Metal complexes include calcium, zinc, iron, and the like.
  • a narrow therapeutic index e.g., the difference between the plasma concentration leading to harmful side effects or toxic reactions and the plasma concentration leading to a therapeutic effect is small; generally, the therapeutic index (TI) is defined as the ratio of median lethal dose (LD 50 ) or median toxic dose (TD 50 ) to median effective dose (ED 50 ); (ii) a narrow absorption window in the gastro- intestinal tract; or (iii) a short biological half-life, so that frequent dosing during a day is required in order to sustain the plasma level at a therapeutic level.
  • a narrow therapeutic index e.g., the difference between the plasma concentration leading to harmful side effects or toxic reactions and the plasma concentration leading to a therapeutic effect is small
  • the therapeutic index (TI) is defined as the ratio of median lethal dose (LD 50 ) or median toxic dose (TD 50 ) to median effective dose (ED 50 );
  • LD 50 median lethal dose
  • TD 50 median toxic dose
  • ED 50 median effective dose
  • controlled release can be obtained by the appropriate selection of formulation parameters and ingredients, including, for example, appropriate controlled release compositions and coatings. Examples include single or multiple unit tablet or capsule compositions, oil solutions, suspensions, emulsions, microcapsules, microspheres, nanoparticulate formulations, patches, and liposomes.
  • Formulations for oral use include tablets containing the active ingredient(s) in a mixture with non-toxic pharmaceutically acceptable excipients.
  • These cxcipients may be, for example, inert diluents or fillers (e.g., sucrose and sorbitol), lubricating agents, glidants, and antiadhesives (e.g., magnesium stearate, zinc stearate, stearic acid, silicas, hydrogenated vegetable oils, or talc).
  • Formulations for oral use may also be provided as chewable tablets, or as hard gelatin capsules wherein the active ingredient is mixed with an inert PATENT
  • ATTORNEY DOCKET NO. 04843/170WO2 solid diluent or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium.
  • Formulations for oral use also include rapidly disintegrating or dissolving dosage forms, also known as fast dissolve, fast or rapid melt, and quick disintegrating dosage forms. These dosage forms dissolve or disintegrate rapidly in the patient's mouth without chewing or the need for water within a short time frame. Because of their ease of administration, such compositions are particularly useful for the specific needs of pediatrics, geriatrics, and for patients with dysphagia.
  • the formulations can be administered to patients in therapeutically effective amounts. For example, an amount is administered which aids recovery of neurological function following brain injury. Typical dose ranges are from about 0.25 mg/kg to about 50 mg/kg of body- weight per day.
  • the exemplary dosage of drug to be administered is likely to depend on such variables as the type and extent of the condition, the overall health status of the particular patient, the formulation of the compound, and its route of administration. Standard clinical trials may be used to optimize the dose and dosing frequency for any particular compound.
  • the compounds of the invention may also be administered by a dose escalating method of acclimatization as described in U.S. Patent No. 5,994,363 thereby ameliorating potential adverse effects.
  • potential adverse effects can be ameliorated by administering R(-)-l 1-hydroxyaporphine compounds in combination with an anti-emetic agent, such as nicotine, lobeline sulfate, pipamazine, oxypendyl hydrochloride, ondansetron, buclizine hydrochloride, cyclizine hydrochloride, dimenhydrinate, scopolamine, metopimazine, benzauinamine hydrochloride or diphenidol hydrochloride.
  • an anti-emetic agent such as nicotine, lobeline sulfate, pipamazine, oxypendyl hydrochloride, ondansetron, buclizine hydrochloride, cyclizine hydrochloride, dimenhydrinate, scopolamine, metopimazine,
  • Example 1 Efficacy of /?(-)- 11 -O-valeryl-N-r ⁇ -propylnoraporphine in an experimental model of stroke recovery in laboratory rats.
  • Surgical occlusion of the middle cerebral artery was utilized to determine the effect of varying doses of /?(-)- 11-O-valeryl-N-r ⁇ - propylnoraporphine in alleviating the neurological deficit resulting from stroke demonstrated as sensorimotor skill performance.
  • Behavioral assessment of compound-treated animals in comparison to control (vehicle-treated) animals was used for evaluating compound efficacy over a 14 day period.
  • MCA occlusion Middle Cerebral Artery Occlusion
  • Focal cerebral infarcts were made by permanent occlusion of the proximal right middle cerebral artery (MCA).
  • ATTORNEY DOCKET NO. 04843/170WO2 the eye and the eardrum canal.
  • the proximal MCA was exposed through a subtemporal craniectomy without removing the zygomatic arch and without transecting the facial nerve.
  • the artery was then occluded by microbipolar coagulation from just proximal to the olfactory tract to the inferior cerebral vein, and transected.
  • Body temperature was maintained at 37.5 ⁇ TC throughout the entire procedure.
  • Each rat received Cefazolin sodium intraperitoneally (i.p.; 40 mg/kg) and Buprenorphine subcutaneously (s.c; ⁇ 0.1 mg/kg) right after the surgery to control pain.
  • the rats were divided into 4 groups of 10 each.
  • Group 1 the control group, received only vehicle.
  • Groups 2, 3, and 4 received doses of R(-)-l l-O-valeryl-N-rc-propylnoraporphine at 0.625, 1.250, or 2.500 mg/kg.
  • Vehicle or R(-)- 11 -O-valeryl-N-w-propylnoraporphine at the above doses was administered twice daily intraperitoneally (BID, i.p.) for 7 days, starting 24 hours post MCA occlusion surgery (see Figure 1).
  • Limb placing tests include assessments of both forelimb and hindlimb placement.
  • the examiner ("blinded," or unaware of the treatment provided) held the rat close to a tabletop and scored the rat's ability to place the forelimb on the tabletop in response to whisker, visual, tactile, or proprioceptive stimulation.
  • the examiner assessed the rat's ability to place the hindlimb on the tabletop in response to tactile and proprioceptive stimulation.
  • the results of the forelimb placing test for medicated and unmedicated (vehicle-treated) rats are provided in Figure 2.
  • the results of the hindlimb placing test for medicated and unmedicated rats are provided in Figure 3.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des procédés et des nécessaires de traitement des accidents vasculaires cérébraux et d'affections associées chez un sujet, grâce à l'administration de R(-)-11-O-valéryl-N-n- propylnoraporphine ou d'un analogue de celle-ci.
PCT/US2009/053839 2008-08-15 2009-08-14 Procédés et nécessaires de traitement des accidents vasculaires cérébraux et autres affections neurologiques WO2010019856A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18913408P 2008-08-15 2008-08-15
US61/189,134 2008-08-15

Publications (1)

Publication Number Publication Date
WO2010019856A1 true WO2010019856A1 (fr) 2010-02-18

Family

ID=41669319

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/053839 WO2010019856A1 (fr) 2008-08-15 2009-08-14 Procédés et nécessaires de traitement des accidents vasculaires cérébraux et autres affections neurologiques

Country Status (1)

Country Link
WO (1) WO2010019856A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1737458A2 (fr) * 2004-04-13 2007-01-03 The McLean Hospital Corporation Derives de r(-)-11-hydroxyaporphines et utilisations de ces derives
CN102532104A (zh) * 2010-12-09 2012-07-04 中国科学院上海药物研究所 一类新型阿朴菲类化合物及其制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316027B1 (en) * 1995-08-18 2001-11-13 R. P. Scherer Technologies, Inc. Fast-dissolving dosage forms for dopamine agonists
US20040242669A1 (en) * 2003-05-27 2004-12-02 Filippo Drago Method of treating deficits associated with brain injury

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316027B1 (en) * 1995-08-18 2001-11-13 R. P. Scherer Technologies, Inc. Fast-dissolving dosage forms for dopamine agonists
US20040242669A1 (en) * 2003-05-27 2004-12-02 Filippo Drago Method of treating deficits associated with brain injury

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LASHUEL ET AL.: "New Class of Inhibitors of Amyloid- Fibril Formation", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 45, 8 November 2002 (2002-11-08), pages 42881 - 42890 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1737458A2 (fr) * 2004-04-13 2007-01-03 The McLean Hospital Corporation Derives de r(-)-11-hydroxyaporphines et utilisations de ces derives
EP1737458A4 (fr) * 2004-04-13 2010-08-04 Mclean Hospital Corp Derives de r(-)-11-hydroxyaporphines et utilisations de ces derives
US8063060B2 (en) 2004-04-13 2011-11-22 The Mclean Hospital Corporation R(−)-11-hydroxyaporphine derivatives and uses thereof
CN102532104A (zh) * 2010-12-09 2012-07-04 中国科学院上海药物研究所 一类新型阿朴菲类化合物及其制备方法和用途
CN102532104B (zh) * 2010-12-09 2014-11-12 中国科学院上海药物研究所 一类阿朴菲类化合物及其制备方法和用途

Similar Documents

Publication Publication Date Title
US20060263427A1 (en) Quinine formulations
CN105143174A (zh) 治疗帕金森疾病的新型高穿透力药物和医药组合物
EP1941880B1 (fr) Préparation sous forme de lotion contenant un dérivé d'acide pyridonecarboxylique
WO2015065867A2 (fr) Agonistes des récepteurs opioïdes kappa périphériques pour prévenir, inhiber ou traiter la nausée et les vomissements
KR20170083509A (ko) 바레니클린 또는 이의 약학적으로 허용가능한 염을 함유하는 맛 차폐된 구강 투여용 약학 제제
MXPA03011314A (es) Formulacion farmaceutica para la administracion eficiente de apomorfina, 6ar-(-)-n-propil-norapomorfina y sus derivados y pro-farmacos de los mismos.
CA2651002A1 (fr) Nouvelles applications de l'escitalopram
TW524690B (en) Use of substituted aminomethyl-chromans for the prevention of neuronal degeneration and for the promotion of neuronal regeneration
TWI814693B (zh) 高穩定性的驅除重金屬組合物及其用途、劑型和製備方法
WO2010019856A1 (fr) Procédés et nécessaires de traitement des accidents vasculaires cérébraux et autres affections neurologiques
JPH0133082B2 (fr)
JP2022535894A (ja) 放出調節製剤およびその使用
EA032064B1 (ru) Способ лечения леводопа-индуцированной дискинезии с применением сиднокарба
US7803842B2 (en) Choline esters useful for the treatment of cognitive dysfunctions and enhancement of memory, learning and cognition
JP2004524270A (ja) 長時間作用する麻酔薬および鎮痛薬としての、三環式抗うつ薬およびのそれらのアナログ
WO2010110428A1 (fr) Agent pour prévenir et/ou traiter le prurit
CN103735545B (zh) 左旋奥拉西坦、奥拉西坦在制备预防或治疗昏迷药物中的应用
ES2483940T3 (es) Un nuevo régimen de dosificación para compuestos moduladores del canal iónico para el tratamiento de la fibrilación auricular aguda en un ser humano
TW589182B (en) Use of 1-(aminoalkyl)-3-quinoxaline-2-on derivatives for the preparation of compositions acting as antioxidants
CN102552248B (zh) 左旋奥拉西坦、奥拉西坦在制备预防或治疗昏迷药物中的应用
CN103800337A (zh) 一类治疗神经退行性疾病的化合物及其用途
Jeong et al. Case Study of Peripheral Vertigo and Nausea Diagnosed as Benign Paroxysmal Positional Vertigo Improved by Traditional Korean Medicine
DE60311134T2 (de) Oromukosale formulierung und herstellungsverfahren dafür
CN103751185B (zh) 左旋奥拉西坦、奥拉西坦在制备预防或治疗昏迷药物中的应用
CN107303392A (zh) 一种聚乙二醇-纳洛酮组合物及应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09807347

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09807347

Country of ref document: EP

Kind code of ref document: A1